

Health Care Market Oversight

AleraCare and Pure Healthcare

The [Health Care Market Oversight](#) (HCMO) program reviews health care business deals to make sure they support Oregon's goals of health equity, lower costs, increased access, and better care. On October 1, 2025, the Oregon Health Authority (OHA) accepted a complete notice of material change describing plans for AleraCare MSO, Inc. ("AleraCare") to acquire Pure Healthcare, LLC ("Pure Healthcare").

Who's involved?

AleraCare is a privately held, for profit corporation based in Arizona. As a management services organization, AleraCare provides non-clinical office support services to infusion clinics in six states. AleraCare does not currently conduct any operations in Oregon.

Pure Healthcare is a privately held, for profit company based in Ohio. Through its subsidiaries, Pure Healthcare operates three lines of business: infusion and injection services, rheumatology services, and neurology services. Pure Healthcare provides these services across 14 states, including Oregon. In 2024, Pure Healthcare served approximately 317 patients at two locations in Oregon (one location is now closed).

About the deal

AleraCare is proposing to acquire Pure Healthcare's infusion and rheumatology business lines. The entities state that they expect AleraCare to support the creation of a new infusion clinic in Oregon. The entities also state that they do not expect the transaction to result in changes to the type and level of services offered in Oregon.

What's next?

OHA is reviewing this deal to understand how it could affect access to care for communities in Oregon. During the review, OHA will use health care data, news and media reports, information from the entities, and public input to decide whether the deal should be approved. After completing a review, OHA will issue a decision about whether the deal may proceed as planned.

We want to hear from you!

Public input helps us understand how this deal could help or harm people in your community. To share your thoughts about this deal, please email hcmo.info@oha.oregon.gov, leave a voicemail at 503-945-6161, or [fill out the public comment form](#). In your comment, mention "AleraCare", what you think, and whether you support or oppose the deal.

You can get this document in other languages, large print, braille, or a format you prefer free of charge. Contact us by email at hcmo.info@oha.oregon.gov or by phone at 503-945-6161. We accept all relay calls.